IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Abroad (travel likely)RecruitingPHASE2

Conditions

CLDN18.2 Positive · Primary Gastric Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Beijing Cancer Hospital, Beijing, Beijing Municipality, China
Contact: Study coordinator (Ziyu Li) · ligregory369@hotmail.com · +8601088196605
Contact: Principal Investigator (Ziyu Li, PhD)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

IBI343 in Combination Therapy for Advanced Malignant Solid Tumors

CLDN18.2 Positive · Gastric/Gastroesophageal Junction Adenocarcinoma · Pancreatic Ductal Adenocarcinoma

Abroad (travel likely)RecruitingPHASE2

Hangzhou, China

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

Gastric Cancer · Gastroesophageal Junction Adenocarcinoma · Esophageal Cancer

Abroad (travel likely)RecruitingPHASE3

Mobile, United States · Anchorage, United States

Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.

Adenocarcinoma

Abroad (travel likely)RecruitingPHASE3

Hefei, China · Hefei, China

Real-WorlD ZolbetUximab in Patients With HER-2 Negative and CLaudin 18.2 PosItive MetastatiC AdEnocarcinoma

Gastric Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma

Abroad (travel likely)Recruiting

Milan, Italy